Role of oxidative stress and insulin resistance in disease severity of non-alcoholic fatty liver disease

Turkish Journal of Gastroenterology

Volumn 27, Issue 4, 2016, Pages 361-366

  Köroǧlu, Emine ^a   Canbakan, Billur ^b   Atay, Kadri ^b   Hatemi, Ibrahim ^b   Tuncer, Murat ^b   Dobrucali, Ahmet ^b   Sonsuz, Abdullah ^b   Gültepe, Ilhami ^c   Şentürk, Hakan ^c  

^a Kartal Dr Lutfi Kirdar Training and Research Hospital   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c BEZMIALEM VAKIF UNIVERSITY   (Turkey)

Author keywords

Insulin resistance; Non alcoholic fatty liver disease; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; GLUTATHIONE; INSULIN; MALONALDEHYDE; NITRIC OXIDE; SUPEROXIDE DISMUTASE;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER BIOPSY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATIENT RISK; PROSPECTIVE STUDY; RISK FACTOR; VITAMIN BLOOD LEVEL; BLOOD; LIVER; PATHOPHYSIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; ASCORBIC ACID; FEMALE; GLUTATHIONE; HUMANS; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MALONDIALDEHYDE; MIDDLE AGED; NITRIC OXIDE; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; SEVERITY OF ILLNESS INDEX; SUPEROXIDE DISMUTASE; VITAMIN E;

EID: 85015283955     PISSN: 13004948     EISSN: 21485607     Source Type: Journal    
DOI: 10.5152/tjg.2016.16106     Document Type: Article

References (35)

1. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28: 360-9.
2. Browning DJ, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-52.
3. Bergamini CM, Gambetti S, Dondi A, Cervellati C. Oxygen, reactive oxygen species and tissue damage. Curr Pharm Des 2004; 10: 1611-26.
4. Sanyal AJ, Campbell SC, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
5. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99: 1497-502.
6. Yesilova Z, Yaman H, Oktenli C, et al. Systemic markers of lipid peroxidation and antioxidants in patients with non-alcoholicfatty liver disease. Am J Gastroenterol 2005; 100: 850-5.
7. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
8. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978; 52: 302-10.
9. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem 1988; 34: 497-500.
10. Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. J Lab Clin Med 1963; 61: 882-8.
11. Omaye ST, Turnbull JD, Sauberlich HE. Selected methods for the determination of ascorbic acid in animal cells, tissues and fluids. Method Enzymol 1979; 6: 3-13.
12. Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003; 17: 24-38.
13. Sundaram SS, Zeitler P, Nadeau K. The metabolic syndrome and nonalcoholic fatty liver disease in children. Curr Opin Pediatr 2009; 21: 529-35.
14. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112.
15. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332: 1519-23.
16. Leach NV, Dronca E, Vesa SC, et al. Serum homocysteine levels, oxidative stress and cardiovascular risk in non-alcoholic steatohepatitis Eur J Int Med 2014; 25: 762-7.
17. Diez-Rodriquez R. Insulin resistance and metabolic syndrome are related to non-alcoholic fatty liver disease, but not visceral adiposity index, in severely obese patients. Rev Esp Enferm Dig 2014; 106: 522-8.
18. Chan DF, Li AM, Chu WC, et al. Hepatic steatosis in obese Chinese children. Int J Obes Relat Metab Disord 2004; 28: 1257-63.
19. Santomauro M, Paoli-Valeri M, Fernández M, et al. Non-alcoholic fatty liver disease and its association with clinical and biochemical variables in obese children and adolescents: effect of a one-year intervention on lifestyle. Endocrinol Nutr 2012; 59: 346-53.
20. Ciba I, Widhalm K. The association between non-alcoholic fatty liver disease and insulin resistance in 20 obese children and adolescents. Acta Paediatr 2007; 96: 109-12.
21. Allard J P, Aghdassi E, Mohammed S, et al. 2008. Nutritional assessment and hepatic fatty acid composition in nonalcoholic fatty liver disease (NAFLD): a cross-sectional study. J Hepatol 48: 300-7.
22. Kondo Y, Masutomi H, Noda Y, et al. Senescence marker protein-30/superoxide dismutase 1 double knockout mice exhibit increased oxidative stress and hepatic steatosis FEBS Open Bio 4 2014; 24: 522-32.
23. Uchiyama S, Shimizu T, Shirasawa T. CuZn-SOD deficiency causes ApoB degradation and induces hepatic lipid accumulation by impaired lipoprotein secretion in mice. J Biol Chem 2006; 281: 31713-9.
24. Ishigami A, Kondo Y, Nanba R, et al. SMP30 deficiency in mice causes an accumulation of neutral lipids and phospholipids in the liver and shortens the life span. Biochem Biophys Res Commun 2004; 315: 575-80.
25. Nobili V, Parola M, Alisi A, et al. Oxidative stress parameters in paediatricnon-alcoholic fatty liver disease International Journal of Molecular Medicine 2010; 26: 471-6.
26. Perlemuter G, Corre M P, Conti M, et al. Increase of liver anti-oxidant enzyme activities in nonalcoholic steatohepatitis (NASH): a defense against an oxidative stress. J Hepatol 2003; 38(Suppl 2): 199.
27. Sreekumar R, Rosado B, Rasmussen D, Charlton M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 2003; 38: 244-51.
28. Cassader M, Gambino R, Musso G, et al. Postprandial triglyceriderich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. Lipids 2001; 36: 1117-24.
29. Canbakan B, Senturk H, Tahan V, et al. Clinical, biochemical and histological correlations in agroup of non-drinker subjects with non-alcoholic fatty liver disease Acta Gastro-Enterologica Belgica 2007; 70: 277-84.
30. Tessari P, Coracina A, Cosma A, Tiengo A. Hepatic lipidmetabolismand non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2009; 19: 291-302.
31. Videla LA, Rodrigo RN, Orellana M, et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci 2004; 106: 261-8.
32. Day C P. Non-alcoholic steatohepatitis (NASH): where arewe nowand where are we going? Gut 2002; 50: 585-8.
33. Evans JL, Maddux BA, Goldfine ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal 2005; 7: 1040-52.
34. Videla LA, Rodrigo R, Araya J, Poniachik J. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med 2006; 12: 555-8.
35. Narasimhan S, Gokulakrishnan K, Sampathkumar R, et al. Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes Clinical Biochemistry 2010; 43: 815-21.